Insight Article Desktop Banner
 
 
Insight Article
  •  
November 01, 2022

The ABCs of Private Equity GP Stakes

Insight Video Mobile Banner
 
November 01, 2022

The ABCs of Private Equity GP Stakes


Insight Article

The ABCs of Private Equity GP Stakes

Share Icon

November 01, 2022

 
 

Private equity firms have become so widely publicized for their activities buying and selling ownership interests in companies that it is often forgotten that private equity firms themselves can be bought and sold. Specialist private equity firms that focus on acquiring and subsequently monetizing ownership interests in other private equity firms, and to a lesser extent, alternative asset sponsors more broadly, have come to be referred to as General Partner (“GP”) stakes firms. The GP stakes bought by these firms have become increasingly prominent in the portfolios of institutional investors over the last decade. These investments are compelling as private equity sponsors are often highly profitable companies in an industry characterized by secular tailwinds and consequently, stakes in these firms have distinct return drivers relative to other private equity strategies. In this primer, we will discuss the basis of what a GP stake is, the private equity industry dynamics that make this style of investing appealing, and the ways in which limited partners can access the attractive return profile offered by the space.

 
 

What is a Private Equity GP Stake?

A GP stake is a non-control, minority equity interest (typically 10%-25%) in the management company of an alternative asset sponsor (“GPs” or “sponsors”). Alternative asset sponsors invest in segments including, but not limited to, private equity, private credit, real estate, infrastructure, and venture capital. Like an ownership stake in any other private or public company, a GP stake is a perpetual and transferable security interest which can be financed, recapitalized, or sold. GP stakes investors are economically entitled to a pro-rata portion of the overall cash flow profile of a given GP, which includes three revenue streams earned by the GP across all its product offerings:

  1. NET FEE-RELATED EARNINGS (“NFRE”):
    Operating income associated with managing the business (e.g., management fees) offset by operating expenses of the business (e.g., employee compensation, office overhead costs, etc.)
  2. CARRIED INTEREST/PERFORMANCE FEES:
    Performance-based fees earned on a given product’s profits
  3. BALANCE SHEET INCOME/CO-INVESTMENT INCOME:
    Returns associated with capital invested as a GP commitment alongside limited partners

A GP stakes investor thus seeks to generate returns from the ongoing distributions related to NFRE, carried interest, and balance sheet income. Distributions of NFRE occur according to an agreed upon periodicity (e.g., bi-annually), offering the GP stakes investor a consistent yield. Carried interest and balance sheet income payment distributions are tied to investment realizations which means precise timing is not known ex-ante, but these distributions offer strong upside potential and are received alongside the sponsor according to pro-rata ownership interest. In addition to these three cash flow components, capital appreciation of the GP stake itself provides added return to the investor. A performing GP stake investment can often be monetized at an attractive price through a sale or financing event.

 
 
DISPLAY 1
 
GP Stake Economic Entitlements
 
 
 

WHY DO SPONSORS SEEK A GP STAKE INVESTOR?

As shown in Exhibit B, catalysts for GP stakes transactions are abundant, but generally arise when a sponsor is either (1) seeking liquidity for existing shareholders (external or internal) of the management company to monetize a portion of the platform’s enterprise value or (2) seeking a capital infusion to finance growth initiatives. For example, this can include scaling existing products or launching new products that may require expanded GP commitments and/or platform enhancements in the form of new hires or investments in organizational infrastructure. Beyond pure financial backing, an engaged GP stakes investor can provide insight into capital and product formation strategies and otherwise advise on institutionalizing the business. As such, depending on its precise motivations for a sale, a sponsor might be keenly focused on what strategic or operational value-add a GP stakes investor can offer.

TYPICAL TERMS OF A PRIVATE EQUITY GP STAKE

The purchase consideration for a GP stake is comprised of two components: primary proceeds and secondary proceeds. Primary proceeds represent any capital that is invested into the sponsor’s business; secondary proceeds represent any liquidity that is provided to management/existing shareholders of the sponsor. The precise consideration paid by a GP stakes investor can take a variety of forms (e.g., cash, working capital, preferred equity, balance sheet investment, etc.) and is based on a sponsor’s unique needs.

The total purchase consideration will be based on an assessment of a sponsor’s franchise value, which will be informed by traditional valuation methods including discounted cash flow and multiple analysis or some combination thereof. Each revenue stream will receive a separate discount rate and multiple which reflects the riskiness of the underlying cash flows. To project cash flows, a GP stakes investor will need to take a view on the performance and asset raising potential of a sponsor across different market environments. As such, a GP stakes investor will evaluate sponsors on a number of areas, including track record, ability to scale either horizontally or vertically, management’s leadership qualities and vision, the broader infrastructure and team that supports management, firm culture, incentive alignment and other talent retention mechanisms.1

GP stakes investors do not seek day-today control of the sponsor but do seek contractual protections to preserve the value of the economic entitlements acquired. For example, the GP stakes investor will seek protections against dilution and look to ensure that key individuals are both contractually tied and economically aligned to the business for the long haul. Other key provisions focus on the ability to generate liquidity and preserve the transferability of the GP stake. Beyond this, there are other negotiated protections and rights, such as information and sponsor access rights, limitations on expenses and incurrence of debt, cooperation covenants with respect to tax matters, and negative consent right over significant events such as changes to the capital structure.

Why are GP Stakes Appealing Investments?

A GP stake affords an investor access to companies with potentially high recurring revenues, high margins, and strong growth prospects driven by secular tailwinds in fundraising.

PRIVATE CAPITAL SPONSOR MODEL TENDS TO BE HIGHLY CASH GENERATIVE

The private market sponsorship model benefits from strong business fundamentals. The income stream from management fees and carried interest can be both steady and substantial.

Management fees are recurring in nature and extend through a fund’s life, offering a contracted revenue stream for a decade or longer. Carried interest revenues are tied to ultimate investment performance gains, and are thus variable in nature, but offer considerable upside potential. Sponsors have operating margins of 40%-70% and very high cash flow conversion as their business has very limited capital expenditure needs.

SECULAR TAILWINDS IN PRIVATE MARKETS

Private markets assets under management (“AUM”) increased by $6.2 trillion from 2010-2021, growing from $2.7 trillion to $8.9 trillion over the referenced period, representing a compound annual growth rate of 11.4%.2

Private markets AUM is forecasted to experience continued growth driven by increased allocations from institutional investors and upside potential in the form of retail investors, who represent a pool of over $50 trillion3 and have historically been an underserved segment by private markets. According to Preqin, AUM in private markets is anticipated to approximately double to $17.8 trillion by 2026; within private markets, private equity represents both the largest share of firms and the fastest growing in terms of AUM, a trend that is anticipated to continue.

The GP stakes industry is expected to continue to grow as a natural consequence of the expansion in private markets more broadly. As private markets have continued to swell, the ability of sponsors to self-finance operations is reduced, creating increased demand for the solutions offered by GP stakes firms.

 
 
DISPLAY 2
 
Potential Motivations for GPs to Seek a GP Stake Investor as a Partner
 

For Illustrative Purposes Only.

 
 

How Can Investors Access GP Stake Investments?

GP staking has been around since the 1980s, but the practice was infrequent and largely limited to institutional investors buying individual stakes in private equity managers often for strategic purposes (e.g., reserve capacity in future fund vintages). For example, Blackstone sold a stake to Nikko Securities in 1988 and CalPERS acquired a 10% stake in the Carlyle Group in 2001. Banks also participated in the space, buying hedge fund stakes to realize business synergies (e.g., prime brokerage).

In the late 2000s, a dedicated and formalized fund management industry developed with the emergence of bulk GP stakes buyers like Goldman Sachs Petershill (2007) and Dyal Capital Partners (2011). Similar to the banks, the original GP stakes firms were primarily focused on hedge funds, but the strategy has evolved to include all alternatives with a marked shift over time to private capital strategies, and in particular, private equity, private credit and real estate. Today, established market participants generally have longstanding fund-of-funds, secondary, and/or private credit businesses, translating into deep relationships with hundreds of sponsors, which can facilitate a successful execution of the strategy. Additionally, sponsors are focused on partnering with funds that project credibility to the broader marketplace and that have durability, which helps explain why the most significant firms in the space have been connected to banks or large alternative asset managers.

 
 
DISPLAY 3
 
EBIT Margins by Sector
 

Source: Capital IQ

 
DISPLAY 4
 
Private Capital AUM Growth
 

Source: Preqin Pro. 2022 Data Pack

 
 

The existing fund offering landscape, which includes products launched by Petershill and Dyal, provides a means for limited partners to access the economics of GP stakes that might otherwise be unattainable given the size (often $100 million to $200 million or more per GP stake investment) and complexity of these transactions, which involve a considerable amount of negotiation and legal documentation. The industry is still evolving and has considerable room to expand as the preponderance of capital raised has been focused on mature GPs and institutional participation remains limited.

Limited partners that would prefer a more hands on approach but face internal resourcing constraints may also consider pursuing a joint venture/anchor or seeding arrangement with a GP stakes specialist.

Partnering with such a group may afford limited partners greater visibility into the GP stakes transaction process and provide other ancillary benefits including preferred economics and/or co-investment rights.

 
 
DISPLAY 5
 
Market Map
 

Source: MSIM Private Markets Team. For illustrative purposes only.

 
 

Conclusion

As the private equity market continues to grow, GP stakes are slated to follow. The GP stakes market offers the opportunity for compelling returns relative to other private equity strategies. An investment in the space takes advantage of the strong capital raising tailwinds in private markets and allows an investor to participate in the fund economics of private capital sponsors which can be quite meaningful. Given the compelling return drivers and flexible entry points, we see GP stakes as an area of private equity where investors should take note.

 
 
Michael Shedosky
Managing Director,
Morgan Stanley Private Credit & Equity
Brian Farrell
Executive Director,
Morgan Stanley Private Credit & Equity
 
 
 
 

DISCLOSURES

The statements above reflect the opinions and views of the Morgan Stanley Alternative Investment Partners Private Markets (“AIP Private Markets Team”) as of the date hereof and not as of any future date and will not be updated or supplemented. All forecasts are speculative, subject to change at any time and may not come to pass due to economic and market conditions.

Information regarding expected market returns and market outlooks is based on the research, analysis, and opinions of the investment team of the AIP Private Markets Team. These conclusions are speculative in nature, may not come to pass, and are not intended to predict the future of any specific Morgan Stanley investment.

Certain information contained herein constitutes forward-looking statements, which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” continue” or “believe” or the negatives thereof or other variations thereon or other comparable terminology. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. No representation or warranty is made as to future performance or such forward-looking statements.

Persons considering an alternative investment should refer to the specific investment’s offering documentation, which will fully describe the specific risks and considerations associated with such investment.

Alternative investments typically have higher fees and expenses than other investment vehicles, and such fees and expenses will lower returns achieved by investors. Alternative investment funds are often unregulated, are not subject to the same regulatory requirements as mutual funds, and are not required to provide periodic pricing or valuation information to investors. The investment strategies described in the preceding pages may not be suitable for the recipient’s specific circumstances; accordingly, you should consult your own tax, legal or other advisors, both at the outset of any transaction and on an ongoing basis, to determine such suitability.

This is prepared for sophisticated investors who are capable of understanding the risks associated with the investments described herein and may not be appropriate for the recipient. No investment should be made without proper consideration of the risks and advice from your tax, accounting, legal or other advisors as you deem appropriate.

Morgan Stanley does not render tax advice on tax accounting matters to clients. This material was not intended or written to be used, and it cannot be used with any taxpayer, for the purpose of avoiding penalties which may be imposed on the taxpayer under U.S. federal tax laws. Federal and state tax laws are complex and constantly changing. Clients should always consult with a legal or tax advisor for information concerning their individual situation.

This material is only intended for and will only be distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.

MSIM, the asset management division of Morgan Stanley (NYSE: MS), and its affiliates have arrangements in place to market each other’s products and services. Each MSIM affiliate is regulated as appropriate in the jurisdiction it operates. MSIM’s affiliates are: Eaton Vance Management (International) Limited, Eaton Vance Advisers International Ltd, Calvert Research and Management, Eaton Vance Management, Parametric Portfolio Associates LLC, and Atlanta Capital Management LLC.

This material has been issued by any one or more of the following entities:

EMEA: This material is for Professional Clients/Accredited Investors only.

In the EU, MSIM and Eaton Vance materials are issued by MSIM Fund Management (Ireland) Limited (“FMIL”). FMIL is regulated by the Central Bank of Ireland and is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson’s Quay, Dublin 2, D02 VC42, Ireland.

Outside the EU, MSIM materials are issued by Morgan Stanley Investment Management Limited (MSIM Ltd) is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA.

In Switzerland, MSIM materials are issued by Morgan Stanley & Co. International plc, London (Zurich Branch) Authorised and regulated by the Eidgenössische Finanzmarktaufsicht (“FINMA”). Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland.

Outside the US and EU, Eaton Vance materials are issued by Eaton Vance Management (International) Limited (“EVMI”) 125 Old Broad Street, London, EC2N 1AR, UK, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority.

Italy: MSIM FMIL (Milan Branch), (Sede Secondaria di Milano) Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy. The Netherlands: MSIM FMIL (Amsterdam Branch), Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. France: MSIM FMIL (Paris Branch), 61 rue de Monceau 75008 Paris, France. Spain: MSIM FMIL (Madrid Branch), Calle Serrano 55, 28006, Madrid, Spain.

NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT

Hong Kong: This material is disseminated by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to “professional investors” as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this material have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this material shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. Singapore: This material is disseminated by Morgan Stanley Investment Management Company and should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore (“SFA”); (ii) to a “relevant person” (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This publication has not been reviewed by the Monetary Authority of Singapore.

Australia: This material is disseminated in Australia by Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accept responsibility for its contents. This publication, and any access to it, is intended only for “wholesale clients” within the meaning of the Australian Corporations Act. Calvert Research and Management, ARBN 635 157 434 is regulated by the U.S. Securities and Exchange Commission under U.S. laws which differ from Australian laws. Calvert Research and Management is exempt from the requirement to hold an Australian financial services licence in accordance with class order 03/1100 in respect of the provision of financial services to wholesale clients in Australia

Japan: For professional investors, this document is circulated or distributed for informational purposes only. For those who are not professional investors, this document is provided in relation to Morgan Stanley Investment Management (Japan) Co., Ltd. (“MSIMJ”)’s business with respect to discretionary investment management agreements (“IMA”) and investment advisory agreements (“IAA”). This is not for the purpose of a recommendation or solicitation of transactions or offers any particular financial instruments. Under an IMA, with respect to management of assets of a client, the client prescribes basic management policies in advance and commissions MSIMJ to make all investment decisions based on an analysis of the value, etc. of the securities, and MSIMJ accepts such commission. The client shall delegate to MSIMJ the authorities necessary for making investment. MSIMJ exercises the delegated authorities based on investment decisions of MSIMJ, and the client shall not make individual instructions. All investment profits and losses belong to the clients; principal is not guaranteed. Please consider the investment objectives and nature of risks before investing. As an investment advisory fee for an IAA or an IMA, the amount of assets subject to the contract multiplied by a certain rate (the upper limit is 2.16% per annum (including tax)) shall be incurred in proportion to the contract period. For some strategies, a contingency fee may be incurred in addition to the fee mentioned above. Indirect charges also may be incurred, such as brokerage commissions for incorporated securities. Since these charges and expenses are different depending on a contract and other factors, MSIMJ cannot present the rates, upper limits, etc. in advance. All clients should read the Documents Provided Prior to the Conclusion of a Contract carefully before executing an agreement. This document is disseminated in Japan by MSIMJ, Registered No. 410 (Director of Kanto Local Finance Bureau (Financial Instruments Firms)), Membership: the Japan Securities Dealers Association, The Investment Trusts Association, Japan, the Japan Investment Advisers Association and the Type II Financial Instruments Firms Association.

 

This is a Marketing Communication.

It is important that users read the Terms of Use before proceeding as it explains certain legal and regulatory restrictions applicable to the dissemination of information pertaining to Morgan Stanley Investment Management's investment products.

The services described on this website may not be available in all jurisdictions or to all persons. For further details, please see our Terms of Use.


Privacy & Cookies    •    Terms of Use

©  Morgan Stanley. All rights reserved.